Amgen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bearish -25

5 Red Days In A Row: Amgen Stock Is Down 15% | Trefis

AI-generated analysis

📉 Amgen stock has fallen 15% over five consecutive trading days, erasing approximately $36 billion in market value.

💊 The decline is linked to Novartis's failed Phase 3 trial for pelacarsen, which negatively impacted investor sentiment toward Amgen's competing olpasiran candidate.

📈 Revenue growth remains strong at 9.1% year-over-year, outpacing the S&P 500 median of 8.3% over the trailing twelve months.

💰 Operating margins stand at 30.0%, significantly higher than the 18.6% median for the broader index.

📊 The stock trades at a P/E multiple of 23.3, which is below the Health Care sector median of 25.1.

💵 Amgen maintains a free cash flow yield of 5.0%, indicating solid cash generation capabilities.

📅 Longer-term momentum persists with +7.2% returns over the trailing three months and +39.2% over twelve months.

Bullish Signals
  • Revenue growth of 9.1% over the last twelve months exceeds the S&P 500 median of 8.3%, demonstrating resilient top-line performance.
  • The company maintains a robust operating margin of 30.0%, which is well above the index median of 18.6%.
  • Amgen generates a free cash flow yield of 5.0%, reflecting strong cash generation relative to its market capitalization.
  • Despite recent volatility, the stock has delivered +7.2% returns over the trailing three months and +39.2% over twelve months.
Risk Factors
  • Shares have dropped 15% over five consecutive days, erasing $36 billion in market value due to a sharp selloff.
  • The stock price fell following Novartis's failed Phase 3 trial for pelacarsen, casting doubt on the commercial viability of Amgen's competing olpasiran candidate.
  • The recent decline places AMGN among 45 other S&P 500 stocks on losing streaks of five days or more, indicating significant short-term momentum weakness.
Full Analysis
Amgen (AMGN) shares have experienced a sharp five-day decline of approximately 15%, erasing roughly $36 billion from its market capitalization and leaving the stock trading at about $204 billion. This significant drop contrasts with broader market performance, as the S&P 500 declined by only 1.2% during the same period, placing Amgen among a select group of stocks facing substantial selling pressure. The recent selloff is directly attributed to clinical trial fallout in the cardiovascular space, specifically following Novartis's failure to meet its primary endpoint for its pelacarsen study. This event cast doubt on the commercial viability of Amgen's competing Phase 3 candidate, olpasiran, triggering a direct spillover effect that drove down AMGN shares despite the company's otherwise sturdy underlying business metrics. Despite the short-term price action, Amgen reports robust trailing fundamentals with revenue growth of 9.1% over the last twelve months and an operating margin of 30.0%, both exceeding S&P 500 medians. The stock currently trades at a price-to-earnings multiple of 23.3, which is below the sector median of 25.1, while maintaining a healthy free cash flow yield of 5.0%. Longer-term performance remains positive with returns of +7.2% over three months and +39.2% over twelve months, suggesting the recent slide may represent a market reassessment rather than a fundamental deterioration. Analysts view such streaks as signals to re-evaluate investment theses against underlying business data rather than immediate instructions to alter positions.